AstraZeneca sales dip but profits up on windfall tax gain

10 November 2016

Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) shares dipped 1% to £45.31 mid-morning after it reported financial results, with sales hit by generic competition for its leading cholesterol drug.

Total Revenue declined 3% at constant exchange rates (-5% actual) in the year to date to $17,417 million, reflecting a decline in product sales that was driven by the entry in the US of multiple Crestor (rosuvastatin) generic medicines. Total sales in the third quarter were $5,699 million, down 4%.

Reported earnings per share (EPS) declined by 26% to $1.31 in the year to date, reflecting the fall in product sales, and were down 4% to $0.80 in the third quarter. Core EPS declined by 10%, to $3.10 reflecting the phasing of other operating Income towards the final quarter of the year, and were up 12% at $1.32 for the third quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK